Abstract

Short Communication

RBD targeted COVID vaccine and full length spike-protein vaccine (mutation and glycosylation role) relationship with procoagulant effect

Luisetto M*, Tarro G, Farhan Ahmad Khan, Khaled Edbey, Mashori GR, Yesvi AR and Latyschev OY

Published: 26 April, 2021 | Volume 5 - Issue 1 | Pages: 001-008

Related COVID vaccine production many different strategies was followed by the producers.

Observing some rare event of thrombosis after some COVID-19 vaccination, it is interesting to verify if the Target used for the manufacturing can be involved in a different procoagulant activity or not.

Some vaccine are suspended in some country or under a deep new verify- investigation by the regulatory agency. (EU or USA).

This fact it is relevant.

The target SPIKE-PROTEIN FULL LENGTH modified or not or towards the RBD domain can be a relevant factor.

Read Full Article HTML DOI: 10.29328/journal.jcavi.1001007 Cite this Article Read Full Article PDF

Keywords:

RBD domain; Spike full length; Mutation; Glycosilation; COVID-19 vaccine; ADR; Thrombosys

References

  1. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2020; 21: 73–82. PubMed: https://pubmed.ncbi.nlm.nih.gov/33340022/
  2. Speiser DE, Bachmann MF. Vaccines COVID-19: Mechanisms of Vaccination and Immunity. Vaccines. 2020; 8: 404. PubMed: https://pubmed.ncbi.nlm.nih.gov/32707833/
  3. Prüβ BM. Review Current State of the First COVID-19 Vaccines. Vaccines 9010030. 2021; 9: 30. PubMed: https://pubmed.ncbi.nlm.nih.gov/33429880/
  4. Yang J, Wang W, Wei X. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020; 586: 572–577. PubMed: https://pubmed.ncbi.nlm.nih.gov/32726802/
  5. Liu Z, Xu W, Xia S, Gu C, Wang X, et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020; 5: 282. PubMed: https://pubmed.ncbi.nlm.nih.gov/33247109/
  6. Zhang S, Liu Y, Wang X, Yang L, Li H, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020; 13: 120. PubMed: https://pubmed.ncbi.nlm.nih.gov/32887634/
  7. Makowski L, Olson-Sidford W, Weisel JW. Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike-protein. Viruses. 2021; 13: 146. PubMed: https://pubmed.ncbi.nlm.nih.gov/33498225/
  8. Brun J, Vasiljevic S, Gangadharan B, Hensen M, Chandran AV, et al. Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine. 2020.
  9. Watanabe Y, Mendonça L, Allen RE, Howe A, Lee M, et al. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222. Vaccine. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/33501433/ 
  10. Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, et al. Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants. medRxiv. 2021. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020991/
  11. Folegatti PM. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. 2020; 396: 467-478.
  12. Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021; 28: 626–639. PubMed: https://pubmed.ncbi.nlm.nih.gov/33479399/
  13. Luisetto M, Almukhtar N, Hamid GA, Khan FA. Spike sars-cov-2 protein as procoagulant factor and vaccine class effect hypothesis. 2021. https://www.researchgate.net/publication/350721725_SPIKE_SARS-COV-2_PROTEIN_AS_PROCOAGULANT_FACTOR_AND_VACCINE_CLASS_EFFECT_HYPOTHESIS
  14. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2020; 21: 73–82. PubMed: https://pubmed.ncbi.nlm.nih.gov/33340022/
  15. Tobaiqy M, Elkout H, MacLure K. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to Eudra Vigilance Database. Vaccines. 2021; 9: 393.
  16. Al-amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, et al. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Scientific Reports. 2021; 7: 44875.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?